Myllia
Private Company
Funding information not available
Overview
Myllia is a Vienna-based biotechnology company leveraging a proprietary, end-to-end functional genomics platform to accelerate early-stage drug discovery. Its differentiated approach utilizes CRISPR screening (CRISPRn, CRISPRi, CRISPRa) in primary human immune and other cell types, coupled with single-cell transcriptomics via CROP-seq, to map gene function and identify high-confidence therapeutic targets. The company operates as a platform and services provider, generating AI-ready datasets for partners in pharma and biotech, with a focus on oncology and autoimmune diseases. Myllia's model aims to de-risk target discovery by providing genetically validated, human-centric data.
Technology Platform
End-to-end functional genomics platform utilizing CROP-seq (CRISPR droplet sequencing) for pooled CRISPR screens (CRISPRn, CRISPRi, CRISPRa) coupled with single-cell RNA sequencing in primary human cells. Enables high-content, mechanism-resolved target discovery and generates AI/ML-ready perturbation datasets.
Opportunities
Risk Factors
Competitive Landscape
Myllia competes in the crowded CRISPR screening services market against large tool companies (e.g., Horizon Discovery), specialized CROs, and academic cores. Its primary differentiator is the focus on high-content, single-cell readouts in primary human cells, a niche less served by standardized, scalable offerings. It also competes indirectly with AI-native drug discovery companies that generate their own data.